medications

Search documents
Get Ready for TrumpRx: Trump Announces Deal With Pfizer to Cut U.S. Drug Prices
Investopedia· 2025-09-30 20:45
Americans enrolled in Medicaid will get "most-favored-nations" pricing, the president said, meaning the U.S. drug prices would match the lower prices of other developed countries. Pfizer will also sell drugs at a direct-to- consumer website that has been dubbed TrumpRx. The government is setting up the website, which will allow Americans to buy medications at prices the government negotiates. Pfizer shares remain in the red for 2025 despite Tuesday's pop. Â ANGELA WEISS / AFP via Getty Images Close KEY TAKE ...
Live: President Trump announces ‘TrumpRx’ drug-buying website, and deal with Pfizer
MSNBC· 2025-09-30 14:50
Watch live coverage as President Trump plans unveil a direct-to-consumer website for Americans to buy drugs, dubbed TrumpRx, while also announcing that Pfizer plans to lower prices on several of its medications in the U.S., according to White House press secretary Karoline Leavitt on X. For more context and news coverage of the most important stories of our day click here: https://www.msnbc.com/ » Subscribe to MSNBC: https://www.youtube.com/msnbc » Subscribe to MSNBC on TikTok https://www.tiktok.com/@msnbc ...
Trump to announce deal with Pfizer to sell drugs at lower prices, Washington Post reports
Reuters· 2025-09-30 14:06
U.S. President Donald Trump will announce an agreement with Pfizer on Tuesday to voluntarily sell the company's medications through Medicaid at lower prices, the Washington Post reported on Tuesday, c... ...
Jim Cramer on Chewy: “You Have My Blessing to Buy it Even After the Rally”
Yahoo Finance· 2025-09-19 03:52
Chewy, Inc. (NYSE:CHWY) is one of the stocks Jim Cramer weighed in on. Cramer discussed the company’s earnings and analyst upgrades following it, as he said: “What on earth happened this quarter that crushed the stock but simultaneously made two analysts feel confident enough to upgrade it? Okay, at first glance, this was a very good quarter… I don’t think the higher SG&A expenses were the real problem. In the end, this was about expectations. Most of Chewy’s numbers came in higher than the consensus anal ...